ARTES offers a range of vaccine producing cell lines and processes for out-licensing and technology transfer. All listed cell lines are based on our safe and high yield yeast expression system Hansenula polymorpha.
| Avian Flu | pre-clinical PoC; based on METAVAX® VLP platform highly immunogenic, adjuvant-free; cell line and process available |
| Hepatitis B | licensed worldwide; new technology with improved yield; RCB, USP, DSP IPC/QC protocols available |
| HPV (L1-6; -11; -16; -18) | RCB, USP, DSP IPC/QC protocols for the different serotypes available |
| Covid (SARS-CoV-2 receptor binding domain (RBD)) | pre-clinical PoC; based on METAVAX® VLP platform highly immunogenic, adjuvant-free; cell line and process available |
To obtain a quote, please contact us at info(at)artes-biotechnology.com indicating name of the vaccine of interest to you. We will revert to you with a dedicated offer specifying delivery times and costs.